The case for & against
Bull & Bear analysis
Bearish
AptarGroup, Inc. (NYSE: ATR) is a leading provider of dispensing and drug delivery solutions, primarily in the pharmaceutical, consumer healthcare, and beauty markets. The company holds a strong positioning in innovative technologies across injectables and nasal drug delivery, particularly as demand for GLP-1 products rises amidst a growing healthcare trend. Aptar is well established in its field, showcasing a diversified portfolio that allows for resilience despite economic fluctuations.
Bull says
- ↑Dividend yield of 0.7% and $131M in dividends/buybacks, including $100M repurchased in Q1
- ↑Q1 revenue up 11% YoY to $984M; adjusted EPS $1.19 despite FX headwinds
- ↑Pharmaceutical injectables (GLP-1) expected to grow high-single to low-double-digits
- ↑Free cash flow of $53M in Q1 and sequential margin improvements planned
- ↑Analyst consensus ‘Strong Buy’ with $150 median price target (~19% upside)
- ↑Net debt $1.1B (leverage 1.43) with low leverage risk and slight undervaluation
Bear says
- ↓$65M revenue headwind from emergency medicine destocking for full-year 2026
- ↓Adjusted EBITDA margin declined to 19.2% due to product-mix and volume shifts
- ↓Rising IP litigation fees could further pressure profit margins
- ↓Weak profitability and earnings yield raise long-term return concerns
- ↓Generic competition threatens pricing power and market share
- ↓Adjusted EPS fell to $1.19 from $1.30 YoY despite 11% sales growth
Investment themes with ATR
High Dividend Yield↑ +0.32%
Companies paying above-average dividends
AVGO · JPM · XOM
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-02-2026neutral
Transcript signals
Bull points
- we will actually increase some of our safety stocks. So I do expect that we'll see a bit of a trend in rising inventory, but for all of the right reasons and done intentionally to make sure that we're well managed through the Middle East crisis and its longer-term impacts.
- we do expect to see sequential margin improvements and closures and that speaks into our guidance
- we feel very good about the prescription growth for the balance of the year.
Bear points
- there was additionally a write-off of a minority investment. It was not the most material item. Stefan just mentioned the maintenance challenges, the weather issues. And this was yet another factor that impacted closures, unfortunately, negatively in the quarter.
- It was a minority investment. It was a venture investment that we made a few years ago. And as we do with all investments, we assess the recoverability of the investment, and we chose to provide against it.
- the further transition from the finger prick with diabetes test strips where we make the vial for the test strips to more um flash glucose monitoring and continuous glucose monitoring as you know we are involved with abbott's libre and lingo so it's more of a matter you know the decline of the first one was the growth of the second one how the balance is out in any given quarter
Read full transcript analysis ›